Physician profile
Steven M Atchison
NPI 1447242276
$169,820.30
in general payments reported to CMS, 2019-2025
23 companies · $13K in 2025
The $13K reported for 2025 was more than what 89% of Orthopaedic Surgery providers received nationally (typical 2025 total: $569).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $46K · 2020: $8,562 · 2021: $32K · 2022: $35K · 2023: $11K · 2024: $25K · 2025: $13K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $39K · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $3,600 · Food and Beverage: $3,400 · Travel and Lodging: $2,555.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $38,900.00 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $3,600.00 |
| Food and Beverage | $3,399.59 |
| Travel and Lodging | $2,555.31 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Stryker Corporation | $145,650.54 | 2019-2025 | Mako, Triathlon, Accolade |
| Heron Therapeutics, INC. | $13,630.80 | 2021-2024 | Zynrelef |
| Medtronic USA, INC. | $9,200.24 | 2019-2020 | |
| Smith+Nephew, INC. | $334.55 | 2019-2025 | Intellio Link Werewolf, N/A, Na |
| Abbvie INC. | $140.55 | 2021-2025 | |
| Pacira Pharmaceuticals Incorporated | $124.99 | 2021 | |
| Curonix LLC | $107.46 | 2025 | Pns Freedom-4a Permanent Neurostimulator Receiver Kit Channel A |
| Pacira Therapeutics, INC. | $93.58 | 2019-2020 | |
| Kci USA, INC. | $72.91 | 2022 | |
| Sanara Medtech INC. | $63.94 | 2021 | |
| Innovation Technologies INC | $63.05 | 2024-2025 | Irrisept |
| Paratek Pharmaceuticals, INC. | $60.07 | 2021-2023 | Nuzyra |
| Medacta USA, INC. | $45.32 | 2022 | |
| Medtronic, INC. | $40.38 | 2021 | |
| Fidia Pharma USA INC. | $26.85 | 2019-2020 |
Show all 23 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Horizon Therapeutics Plc | $26.04 | 2020 | |
| Solventum Corporation | $25.13 | 2025 | V.A.C. Veraflo |
| Sanofi-Aventis U.S. LLC | $24.15 | 2019 | |
| Convatec INC. | $21.78 | 2024 | |
| Axogen | $19.80 | 2020 | |
| Bioventus LLC | $17.99 | 2024 | Exogen Ultrasound Bone Healing System |
| Vericel Corporation | $15.86 | 2019 | |
| Depuy Synthes Sales INC. | $14.32 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Steven Atchison listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.